Latest SNSE reports update at 2024-05-09: 2024-Q1 ∙ 2023-Q4 ∙ 2023-Q1

Sensei Biotherapeutics SNSE

$ 1.57 -14.67%

Sensei Biotherapeutics Financial Statements 2011-2024 | SNSE

Annual Financial Statements Sensei Biotherapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	24 M	40.8 M	134 M	-	-	-	-	-	-	-	-	-	-
Shares	28 M	30.7 M	27.7 M	-	-	-	-	-	-	-	-	-	-
Historical Prices	0.86	1.33	4.82	-	-	-	-	-	-	-	-	-	-
Net Income	-34.1 M	-48.6 M	-36.8 M	-20.1 M	-16.7 M	-13 M	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-37.1 M	-50.2 M	-37.5 M	-19.5 M	-	-	-	-	-	-	-	-	-
Interest Expense	144 K	219 K	670 K	1.69 M	-	-	-	-	-	-	-	-	-
EBITDA	-36.5 M	-49.6 M	-36.8 M	-18.5 M	-12.4 M	-12.7 M	-	-	-	-	-	-	-
Operating Expenses	37.1 M	50.2 M	37.5 M	18.7 M	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	18.8 M	19.8 M	15.8 M	7.53 M	4.08 M	4.51 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Sensei Biotherapeutics

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	25 M	25 M	25.5 M	30.5 M	30.9 M	30.8 M	30.7 M	30.7 M	30.6 M	30.6 M	30.6 M	30.6 M	18.9 M	1.88 M	1.79 M	1.63 M	1.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-7.99 M	-	-7.12 M	-9.39 M	-10.2 M	-	-13.4 M	-10.5 M	-12.4 M	-	-9.68 M	-9.77 M	-7.97 M	-	-5.37 M	-4.91 M	-4.69 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-8.73 M	-	-7.74 M	-10.2 M	-11 M	-	-13.9 M	-10.7 M	-12.5 M	-	-10.3 M	-9.78 M	-7.97 M	-	-5.36 M	-4.91 M	-4.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	28 K	-	33 K	38 K	42 K	-	10 K	172 K	243 K	-	214 K	147 K	3 K	-	3 K	3 K	1.63 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-8.59 M	-	-7.6 M	-10 M	-10.8 M	-	-13.8 M	-10.6 M	-12.3 M	-	-10.2 M	-9.66 M	-7.87 M	-	-5.3 M	-4.86 M	-4.08 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	8.73 M	-	7.74 M	10.2 M	11 M	-	13.9 M	10.7 M	12.5 M	-	10.3 M	9.78 M	7.97 M	-	5.36 M	4.91 M	4.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	3.81 M	-	3.92 M	5.39 M	5.8 M	-	4.75 M	4.32 M	5.03 M	-	3.87 M	3.89 M	4.6 M	-	1.79 M	1.31 M	1.91 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency